

FOR ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

NOW APPROVED THE FIRST FDA-APPROVED MEDICINE OF ITS KIND* TO TREAT ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS)

Patient portrayal.

*COSENTYX targets and blocks IL-17A, a molecule believed to play a role in the inflammation that may contribute to HS symptoms.

INDICATIONS

COSENTYX[®] is a prescription medicine used to treat:

- people 6 years of age and older with moderate to severe plaque psoriasis (PsO) that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light alone or with systemic therapy)
- people 2 years of age and older with active psoriatic arthritis (PsA)
- adults with active ankylosing spondylitis (AS)
- adults with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation
- people 4 years of age and older with active enthesitis-related arthritis (ERA)
- adults with moderate to severe hidradenitis suppurativa (HS)

IMPORTANT SAFETY INFORMATION

Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.



COSENTYX[®] IS PROVEN TO WORK DIFFERENTLY

COSENTYX targets and blocks IL-17A*, a molecule that is thought to play a role in inflammation that can lead to hidradenitis suppurativa (HS) symptoms.

Before the FDA approved COSENTYX for the treatment of hidradenitis suppurativa for adults with moderate to severe HS, **over 3.7 million COSENTYX prescriptions** had been filled^{*} in the United States.[†]

TAKE ON HS—FROM THE INSIDE OUT.

Talk with your dermatologist to see if COSENTYX may be right for you.

*The relationship between how COSENTYX works in the body and how it affects your symptoms is unknown.

[†]As of March 2023

[‡]Across all indications, not including HS.

IMPORTANT SAFETY INFORMATION (continued) What is the most important information I should know about COSENTYX?

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

Infections

COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have died from these infections.

- Your doctor should check you for tuberculosis (TB) before starting treatment with COSENTYX.
- If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX.
- Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. Do not use COSENTYX if you have an active TB infection.

atient portrayal.

Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.



ABOUT HS

WHAT IS HIDRADENITIS SUPPURATIVA (HS)?

While the exact cause is unknown, it is thought that HS symptoms start with a blocked hair follicle that triggers the immune system, producing too many inflammatory molecules, like IL-17A. In people with HS, an overactive immune system and too much IL-17A are thought to contribute to excess inflammation in the body that may cause bumps and abscesses that can hurt.

IN HS, IT IS THOUGHT THAT AN OVERACTIVE IMMUNE SYSTEM ATTACKS BLOCKED HAIR FOLLICLES.

Inflammation can cause hair follicles to become blocked and enlarged.

HS CAN HAPPEN TO ALMOST ANYONE

IT'S NOT CONTAGIOUS OR DUE TO POOR HYGIENE.

- One in 100 people may be affected by HS.
- HS usually begins when people are in their 20s.
- HS is more common in women and affects people of color disproportionately.
- Other factors that may contribute to HS symptoms getting worse include one's weight or smoking.

Blocked and enlarged hair follicles can rupture, causing painful bumps and boil-like abscesses.



Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.




HS CAN FEEL LIKE IT TAKES OVER

Living with hidradenitis suppurativa (HS) can be a long and frustrating journey. Often, dealing with painful HS symptoms can make everyday activities a challenge.

HS signs and symptoms can include painful bumps or abscesses, mostly in areas where skin rubs against skin, like the armpits, the groin area, inner thighs, buttocks, and under the breasts. HS abscesses can drain and may lead to tunnels that can leave scars.

WHERE HS SYMPTOMS COMMONLY APPEAR:



HOW HS MAY PROGRESS

Over time, HS may progress or get worse if left untreated, and may lead to scarring; that's why it's important to understand more about HS.

HS CAN BE CLASSIFIED INTO 3 STAGES* BASED ON THE SEVERITY OF THE SYMPTOMS:



MILD[†] is when there is 1 bump or multiple inflammatory bumps and abscesses, with no scarring or tunnel (sinus tract) formation.



MODERATE is when there are multiple abscesses, along with limited tunnels and/or scarring.



SEVERE is when there are multiple or extensive interconnected tunnels, abscesses, and scarring.

All images used with permission from ©DermNet NZ

 * In classifying the severity of your condition, your dermatologist may call these Hurley stages.

[†]COSENTYX is approved to treat moderate to severe HS.

IMPORTANT SAFETY INFORMATION (continued) Before starting COSENTYX°, tell your doctor if you:

- are being treated for an infection
- have an infection that does not go away or that keeps coming back
- have TB or have been in close contact with someone with TB

Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.



COSENTYX[®] IS THE FIRST FDA-APPROVED MEDICINE OF ITS KIND TO TREAT ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA (HS)

HOW IS COSENTYX DIFFERENT?

COSENTYX targets and blocks IL-17A,* a molecule thought to play a role in the inflammation that may contribute to HS symptoms. Some IL-17A is normal, but when you have HS, too much inflammation may cause HS symptoms like bumps and abscesses that can hurt.

COSENTYX is a biologic—a protein-based medication that is made from living sources and taken by injection.

 * The relationship between the way COSENTYX works in the body and how it affects HS symptoms is not fully known.



SCAN CODE TO SEE HOW COSENTYX TREATS HS FROM THE INSIDE OUT.

IMPORTANT SAFETY INFORMATION (continued) Before starting COSENTYX[®], tell your doctor if you:

 think you have an infection or have symptoms of an infection such as: fevers, sweats, or chills; muscle aches; cough; shortness of breath; blood in your phlegm; weight loss; warm, red, or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal

After starting COSENTYX, call your doctor right away if you have any signs of infection listed on page 7 and above. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.

PROVEN EXPERIENCE

COSENTYX has had a well-studied safety profile since its launch in 2015 and has been approved to treat numerous conditions:

2015 – adults with moderate to severe plaque psoriasis

2016 – adults with active ankylosing spondylitis and active psoriatic arthritis

2020 – adults with active non-radiographic axial spondyloarthritis

2021 – children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-realted arthritis (4 years and older)

2023 – adults with moderate to severe hidradenitis suppurativa



Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.

FIND REAL RELIEF FROM HS SYMPTOMS

COSENTYX[®] is proven to help adults with moderate to severe hidradenitis suppurativa (HS) **FIND RELIEF** at **16 WEEKS.***



REDUCTION

At least a 50% reduction in the number of inflammatory bumps and abscesses.



RESULTS

NO INCREASE

in the number of abscesses and/or draining tunnels.

In the 2 clinical trials, 41% and 43% of adults taking COSENTYX* had at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels at 16 weeks vs 29% and 26% taking placebo.

* COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses).

IMPORTANT SAFETY INFORMATION (continued) What are the possible side effects of COSENTYX?

COSENTYX may cause serious side effects, including:

Serious allergic reactions

Serious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; skin rash or hives (red, itchy bumps).

If you have a severe allergic reaction, do not give another injection of COSENTYX.

Inflammatory bowel disease

New cases of inflammatory bowel disease or "flare-ups" can happen with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn's disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.



Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>. RESULTS



COSENTYX° CAN HELP REDUCE HS FLARES



IN 1 OF 2 CLINICAL TRIALS, 75% OF ADULTS TAKING COSENTYX HAD ZERO FLARES AT WEEK 16.

In the same clinical trial, 25% of adults taking COSENTYX* had 1 or more flares at week 16 vs 36% taking placebo. **In the second trial, the same results were not seen.**

A flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses, with a minimum increase of 2 inflammatory bumps or abscesses.

IMPORTANT SAFETY INFORMATION (continued) Severe skin reactions that look like eczema can happen during treatment with COSENTYX from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with COSENTYX if you develop severe skin reactions. Tell your doctor if you have any of the following signs or symptoms: redness or rash; itching; small bumps or patches; your skin is dry or feels like leather; blisters on the hands or feet that ooze or become crusty or skin peeling.

The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory tract infections.

These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.

Before using COSENTYX, tell your doctor if you:

- have any of the conditions or symptoms listed above for infections.
- have inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- are allergic to latex. The needle cap on the COSENTYX Sensoready[®] pen, and 150 mg/mL and 75 mg/0.5 mL prefilled syringes contains latex.



RESULTS

Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.

Visit COSENTYX.com for more information.

RESULTS

AT 1 YEAR OF TREATMENT*

The 1-year information presented here is exploratory data[†] and it is unknown if symptom improvement was due to COSENTYX[®] or not. Everyone experiences treatment differently, so results may vary.

BUMPS AND ABSCESSES AT 1 YEAR

In the 2 clinical trials, at 1 year, 58% and 65% (56 out of 96, 61 out of 94 patients, respectively) had at least a 50% reduction in the number of inflammatory bumps and abscesses, with no increase in the number of abscesses and/or draining tunnels.

FLARES AT 1 YEAR

RESULTS

At 1 year, 72% and 74% (78 out of 109 and 75 out of 102 patients, respectively) did not experience a flare. In the clinical trials, a flare was defined as a greater than 25% increase in the number of inflammatory bumps and abscesses, with a minimum increase of 2 inflammatory bumps or abscesses.

*COSENTYX 300 mg every 4 weeks (after 5 initial weekly doses), as reported by the people in the trial.

[†]We cannot make conclusions from exploratory data, but it is useful to help guide future research.

TALK TO YOUR DERMATOLOGIST ABOUT YOUR TREATMENT GOALS, INCLUDING BUMPS, FLARES, AND SKIN PAIN.

IMPORTANT SAFETY INFORMATION (continued)

- have recently received or are scheduled to receive an immunization (vaccine). People who take COSENTYX should not receive live vaccines. Children should be brought up to date with all vaccines before starting COSENTYX.
- have any other medical conditions and all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.

IMPORTANT SAFETY INFORMATION (continued) are pregnant or plan to become pregnant. It is not

- Are pregnant or ptan to become pregnant, it is not known if COSENTYX can harm your unborn baby. You and your doctor should decide if you will use COSENTYX.
- are breastfeeding or plan to breastfeed. It is not known if COSENTYX passes into your breast milk.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/ medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.

(secukinumab)

Patient portrayal.



CONVENIENT DOSING

The recommended dose of COSENTYX® for hidradenitis suppurativa (HS) is 300 mg.* If your doctor decides that you or a caregiver may give your injections at home, you should receive training on the right way to prepare and inject COSENTYX. Do not try to inject COSENTYX yourself, until you or your caregiver have been shown how by your doctor.

GETTING STARTED ON COSENTYX:

Once weekly for 5 weeks.



STAYING ON COSENTYX:

Once every 4 weeks. If you continue to have HS symptoms, your dermatologist may prescribe COSENTYX every 2 weeks.



*Each 300-mg dose is given as 1 injection of 300 mg or 2 injections of 150 mg under the skin.

IMPORTANT SAFETY INFORMATION

Do not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

What is the most important information I should know about COSENTYX?

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

Infections

COSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections. Some people have died from these infections.

GET COMFORTABLE TAKING COSENTYX

The 300-mg UnoReady Pen is easy to use and has a 100% satisfaction rating.*

- Most people experience no pain with the injection[†]
- The cap is not made with natural rubber latex



*Based on a study in which all 37 participants using the UnoReady Pen reported being satisfied or very satisfied with the device at 28 weeks for patients with moderate to severe PsO patients.

 † Based on a study in which 30 of 38 participants using the UnoReady Pen reported no pain with the injection at 12 weeks.

Read the detailed "Instructions for Use" that comes with your COSENTYX for information on how to prepare and inject a dose of COSENTYX, and how to properly throw away (dispose of) used COSENTYX..

	R,	
705	į,	
÷,		
	. 65	

WATCH HOW TO INJECT USING THE UNOREADY® PEN AND OTHER INJECTION RESOURCES

IMPORTANT SAFETY INFORMATION (continued)

- Your doctor should check you for tuberculosis (TB) before starting treatment with COSENTYX.
- If your doctor feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with COSENTYX and during treatment with COSENTYX.
- Your doctor should watch you closely for signs and symptoms of TB during treatment with COSENTYX. Do not use COSENTYX if you have an active TB infection.

Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.

Visit COSENTYX.com for more information.

DOSING



REAL SUPPORT. PERSONAL SOLUTIONS.

COSENTYX® Connect is a free support program

that's tailored to your needs right from the start. Here's what you will get once you sign up:



Dedicated COSENTYX® Connect Team to help you get started



\$0 co-pay* offer

if you are eligible. Subject to annual benefit limit. Additional limitations apply.



Up to 2 years of COSENTYX for free with the Covered Until You're Covered program⁺ if your insurance coverage is denied



Help with navigating insurance coverage



e-mail, and text updates

Personalized resources via mail.



*Limitations apply. Valid only for those with private insurance. Program provides up to \$16,000 annually for the cost of COSENTYX and up to \$150 per infusion (up to \$1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

To enroll in the COSENTYX® Connect Support Program and start receiving these free resources, call us at **1-844-COSENTYX** (1-844-267-3689) or visit COSENTYX.com.

For more details, see the following page.

GETTING STARTED ON COSENTYX

Your COSENTYX[®] Connect Checklist makes the process of getting started on COSENTYX as simple as 1, 2, 3, and 4.



SCAN THIS CODE FOR A CHECKLIST TO USE WHEN GETTING STARTED ON COSENTYX



Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.



GETTING HELP NAVIGATING YOUR COVERAGE

Your COSENTYX[®] Connect team will work with you and your healthcare provider to get your COSENTYX[®] (secukinumab) prescription approved.



You may be eligible to save on your prescription out-of-pocket costs every month.

GETTING FINANCIAL ASSISTANCE

You may be eligible for our **\$0 co-pay* offer** if you are privately insured. In 2022, 94% of patients who used the program paid \$0 out of pocket.

In the unlikely event that your coverage is denied, we'll do everything we can to help. Learn more about our Covered Until You're Covered Program.[†] The program offers up to 2 years of COSENTYX for free if your coverage isn't initially approved.

For more coverage assistance, go to COSENTYX.com/how-to-get-cosentyx for a full walk-through of the steps for getting COSENTYX.

GETTING COSENTYX DELIVERED

COSENTYX is sent to you from a specialty pharmacy since it's a biologic medication, which means it requires special handling and must be refrigerated.



SCAN TO LEARN MORE ABOUT HOW COSENTYX[®] CONNECT CAN HELP

SHARE YOUR HS STORY

If you're taking COSENTYX for any of its FDA approved indications and would like to help others, share your story with us. After you do, a member of your our Voices of Inspiration staff will get in touch.



SCAN TO LEARN HOW TO SHARE YOUR STORY THROUGH VOICES OF INSPIRATION

Or visit COSENTYX.com/hidradenitis-suppurativa/ share-treatment-story.

*Limitations apply. Valid only for those with private insurance. Program provides up to \$16,000 annually for the cost of COSENTYX and up to \$150 per infusion (up to \$1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

[†]The Covered Until You're Covered Program is available for COSENTYX subcutaneous injection only. Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to 2 years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after 2 years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.

Visit COSENTYX.com for more information.


SUPPORT



START THE CONVERSATION WITH A DERMATOLOGIST

Answer 5 simple questions to help guide your conversation and treatment goals with your doctor. We also provided space for you to write down any additional questions.

1. Circle the areas where you have bumps or abscesses:



2. Have you experienced these symptoms more than once in the same area(s) in a 6-month period?

□ Yes □ No

3. What symptoms do you experience with these bumps and abscesses?

Check all that apply.

🗅 Pain	Swelling	L Itching
Leaking or d	•	🗅 Odor
pus and/or b	lood	

• Other

4. Which of your daily activities are negatively affected by your condition?

Check all that apply.	
Getting dressed	Going to work
Exercising	Making plans
Other	

5. Are you satisfied with your current treatment?

Yes

I'm not currently treating my hidradenitis suppurativa (HS).

SUPPORT





ASK YOUR DERMATOLOGIST ABOUT COSENTYX®.

Visit COSENTYX.com/hidradenitis-suppurativa







Please see additional Important Safety Information throughout brochure. Click here for full <u>Prescribing Information</u>, including <u>Medication Guide</u>.



Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 © 2023 Novartis Printed in USA